COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

COST

1,026.56

+2.01%↑

PG

163.14

+0.44%↑

KO

72.16

+0.75%↑

PM

170.41

+0.53%↑

PEP

132.08

+0.77%↑

Search

Hims & Hers Health Inc

Aperta

SettoreConsumatore difensivo

61.26 7.06

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

56.5

Massimo

63.4

Metriche Chiave

By Trading Economics

Entrata

23M

49M

Vendite

105M

586M

P/E

Media del settore

81.191

42.52

EPS

0.2

Margine di Profitto

8.444

Dipendenti

1,637

EBITDA

39M

58M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

-25.56% downside

Dividendi

By Dow Jones

Utili prossimi

4 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

3.2B

12B

Apertura precedente

54.2

Chiusura precedente

61.26

Notizie sul Sentiment di mercato

By Acuity

20%

80%

16 / 151 Classifica in Consumer defensive

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Hims & Hers Health Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 apr 2025, 12:54 UTC

I principali Market Mover

Hims & Hers Rallies After Novo Nordisk Deal on Wegovy

4 apr 2025, 22:38 UTC

Azioni calde

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1 apr 2025, 23:15 UTC

I principali Market Mover

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25 feb 2025, 15:33 UTC

I principali Market Mover

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18 nov 2024, 19:07 UTC

I principali Market Mover

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14 ott 2024, 15:02 UTC

I principali Market Mover

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

3 ott 2024, 11:28 UTC

I principali Market Mover

Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List

7 mag 2025, 13:56 UTC

Utili

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

6 mag 2025, 14:24 UTC

Utili

Hims & Hers Stock Is Higher After Earnings. The Sales Outlook Looks Low. -- Barrons.com

30 apr 2025, 09:30 UTC

Notizie principali

Why New Wegovy Deals Won't Restore Novo's Obesity Lead -- Heard on the Street -- WSJ

2 apr 2025, 16:53 UTC

Notizie principali

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19 mar 2025, 15:54 UTC

Notizie principali

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21 feb 2025, 23:20 UTC

Utili

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10 feb 2025, 12:00 UTC

Notizie principali

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19 dic 2024, 17:16 UTC

Notizie principali

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19 dic 2024, 15:14 UTC

Notizie principali

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19 dic 2024, 15:02 UTC

Notizie principali

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16 dic 2024, 13:47 UTC

Notizie principali

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16 dic 2024, 07:00 UTC

Notizie principali

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3 ott 2024, 14:45 UTC

Notizie principali

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3 ott 2024, 13:12 UTC

Notizie principali

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 ott 2024, 11:45 UTC

Notizie principali

Update: Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 ott 2024, 10:14 UTC

Notizie principali

Update: Eli Lilly's Weight-Loss Drugs No Longer In Shortage. It's Bad News for These Stocks. -- Barrons.com

2 ago 2024, 17:52 UTC

Acquisizioni, Fusioni, Takeovers

Hims & Hers Plan to Sell Knockoff Weight Loss Drug Looking Shaky -- Barrons.com

26 giu 2024, 11:00 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

The War Over Cheaper Ozempic Won't End Well for Some Investors -- Heard on the Street -- WSJ

24 mag 2024, 20:37 UTC

Utili

The Score: Target, Nvidia, Live Nation and More Stocks That Defined the Week -- WSJ

Confronto tra pari

Modifica del prezzo

Hims & Hers Health Inc Previsione

Obiettivo di Prezzo

By TipRanks

-25.56% in calo

Previsioni per 12 mesi

Media 45.5 USD  -25.56%

Alto 85 USD

Basso 25 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hims & Hers Health Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

14 ratings

4

Acquista

8

Mantieni

2

Vendi

Punteggio Tecnico

By Trading Central

36.685 / 52.35Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

16 / 151 Classifica in Consumatore difensivo

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.